Skip to main content


Log in

The efficacy of dupilumab in induction and maintenance of remission in an adult patient with steroid-dependent eosinophilic enteritis (EoN)

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript


Eosinophilic enteritis (EoN) is associated with an eosinophilic infiltrate confined to the small intestine, but treatment options other than diet and corticosteroid therapy are scarce. There is only one report of the use of dupilumab for eosinophilic gastrointestinal disease, involving three pediatric patients. We report a case of successful induction of remission with dupilumab in a 53 year-old female patient with steroid-dependent EoN. The patient presented to the emergency room with uncontrollable abdominal pain and CT revealed a thickened ileal wall and small amount of ascites. Despite no abnormalities on endoscopy, histological examination revealed numerous eosinophilic infiltrates (> 100/HPF) and degranulation in the ileal lamina propria, diagnosing the patient with EoN. The patient achieved clinical remission with prednisolone, but EoN relapsed during tapering. Long-term steroid therapy was inappropriate due to mandibular osteomyelitis and osteoporosis, and she was switched to 9 mg budesonide, an intestine-soluble topical steroid without effect. Dupilumab administration resulted in resolution of abdominal pain, and remission was maintained after discontinuation of budesonide. Histological remission was confirmed 2 months after dupilumab administration. This is the first report of remission induced and maintained with dupilumab in an adult patient with EoN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others



Eosinophilic gastrointestinal disease


Eosinophilic esophagitis


Eosinophilic enteritis


EGID distal to the esophagus


Non-steroidal anti-inflammatory drugs


Thymus- and activation-regulated chemokine


  1. Licari A, Votto M, D’Auria E, et al. Eosinophilic gastrointestinal diseases in children: a practical review. Curr Pediatr Rev. 2020;16:106–14.

    Article  PubMed  Google Scholar 

  2. Dellon ES, Gonsalves N, Abonia JP, et al. International consensus recommendations for eosinophilic gastrointestinal disease nomenclature. Clin Gastroenterol Hepatol. 2022;20:2474-84.e3.

    Article  PubMed  Google Scholar 

  3. Mansoor E, Saleh MA, Cooper GS. Prevalence of eosinophilic gastroenteritis and colitis in a population-based study, from 2012 to 2017. Clin Gastroenterol Hepatol. 2017;15:1733–41.

    Article  PubMed  Google Scholar 

  4. Pineton de Chambrun G, Gonzalez F, Canva JY, et al. Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2011;9:950-6.e1.

    Article  PubMed  Google Scholar 

  5. Chen PH, Anderson L, Zhang K, et al. Eosinophilic gastritis/gastroenteritis. Curr Gastroenterol Rep. 2021;23:13.

    Article  PubMed  Google Scholar 

  6. Patel N, Goyal A, Thaker A, et al. A case series on the use of dupilumab for treatment of refractory eosinophilic gastrointestinal disorders. J Pediatr Gastroenterol Nutr. 2022;75:192–5.

    Article  PubMed  Google Scholar 

  7. Zhang M, Li Y. Eosinophilic gastroenteritis: a state-of-the-art review. J Gastroenterol Hepatol. 2017;32:64–72.

    Article  PubMed  Google Scholar 

  8. Anuradha C, Mittal R, Yacob M, et al. Eosinophilic disorders of the gastrointestinal tract: imaging features. Diagn Interv Radiol. 2012;18:183–8.

    PubMed  Google Scholar 

  9. Zhang L, Duan L, Ding S, et al. Eosinophilic gastroenteritis: clinical manifestations and morphological characteristics, a retrospective study of 42 patients. Scand J Gastroenterol. 2011;46:1074–80.

    Article  PubMed  Google Scholar 

  10. Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009;29:765–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63:262–71.

    Article  CAS  PubMed  Google Scholar 

  12. Tan AC, Kruimel JW, Naber TH. Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets. Eur J Gastroenterol Hepatol. 2001;13:425–7.

    Article  CAS  PubMed  Google Scholar 

  13. Siewert E, Lammert F, Koppitz P, et al. Eosinophilic gastroenteritis with severe protein-losing enteropathy: successful treatment with budesonide. Dig Liver Dis. 2006;38:55–9.

    Article  CAS  PubMed  Google Scholar 

  14. Friesen CA, Kearns GL, Andre L, et al. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr. 2004;38:343–51.

    Article  PubMed  Google Scholar 

  15. Schwartz DA, Pardi DS, Murray JA. Use of montelukast as steroid-sparing agent for recurrent eosinophilic gastroenteritis. Dig Dis Sci. 2001;46:1787–90.

    Article  CAS  PubMed  Google Scholar 

  16. Sheikh RA, Prindiville TP, Pecha RE, et al. Unusual presentations of eosinophilic gastroenteritis: case series and review of literature. World J Gastroenterol. 2009;15:2156–61.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Gonsalves N. Eosinophilic gastrointestinal disorders. Clin Rev Allergy Immunol. 2019;57:272–85.

    Article  PubMed  Google Scholar 

  18. Shoda T, Wen T, Caldwell JM, et al. Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study. J Allergy Clin Immunol. 2020;145:255–69.

    Article  CAS  PubMed  Google Scholar 

  19. Pesek RD, Gupta SK. Future therapies for eosinophilic gastrointestinal disorders. Ann Allergy Asthma Immunol. 2020;124:219–26.

    Article  PubMed  Google Scholar 

  20. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387:2317–30.

    Article  CAS  PubMed  Google Scholar 

  21. Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10:11–25.

    Article  CAS  PubMed  Google Scholar 

Download references


The authors would like to thank Enago ( for the English language review.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Sho Watanabe.

Ethics declarations

Conflict of interest

The authors state that they have no conflict of interest.

Ethical approval

The administration of budesonide and dupilumab to this EoN patient with severe asthma was done after obtaining the approval of the ethics review committee of Soka municipal hospital and the informed consent of the patient.

Informed consent

Written informed consent was given by the patient for the publication of this manuscript. Identifying information, aside from age and sex, was removed and the images provided were anonymized to protect patient confidentiality.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Watanabe, S., Uchida, H., Fujii, R. et al. The efficacy of dupilumab in induction and maintenance of remission in an adult patient with steroid-dependent eosinophilic enteritis (EoN). Clin J Gastroenterol 16, 527–531 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: